Predict your next investment

HEALTHCARE | Biotechnology
combigene.com

See what CB Insights has to offer

Founded Year

2008

Stage

IPO | IPO

Total Raised

$4.27M

Date of IPO

12/19/2018

Market Cap

0.16B

About CombiGene

CombiGene is developing treatment methods for epilepsy patients. Combining advances in neuroscience and modern genetic engineering, CombiGene developed a treatment method that, in preclinical studies, proved to prevent epilepsy cases. The company is focusing on further developing this treatment method to accommodate epilepsy patients.

CombiGene Headquarter Location

Scheelevagen 2 Medicon Village

Lund, 223-81,

Sweden

Latest CombiGene News

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs In Development, 2021 Research Report Featuring CombiGene, Gila Therapeutics, Takeda Pharmaceutical, XL-protein - ResearchAndMarkets.com

Jul 20, 2021

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor. The report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy. Scope The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics Key Topics Covered: Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones Featured News & Press Releases Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities' positive response Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene's plan for CG01's final preclinical studies Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01 Dec 14, 2020: With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01 Oct 30, 2020: CombiGene comments the final preclinical steps Oct 01, 2020: CombiGene one step closer to clinical trials Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene's AAV-based gene therapy for the treatment of epilepsy Sep 11, 2020: CombiGene's new agreement important for future clinical studies Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01 Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01 Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene's epilepsy gene therapy drug candidate Appendix

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CombiGene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CombiGene is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

CombiGene Patents

CombiGene has filed 2 patents.

The 3 most popular patent topics include:

  • Animal virology
  • Molecular biology
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/4/2007

12/2/2014

G protein coupled receptors, Molecular biology, Peptides, Peptide hormones, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/4/2007

00/00/0000

Grant Date

12/2/2014

00/00/0000

Title

Subscribe to see more

Related Topics

G protein coupled receptors, Molecular biology, Peptides, Peptide hormones, Genetics

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.